/CC
CC Stock - The Chemours Company
Basic Materials|Chemicals - SpecialtyNYSE
$11.82-0.42%
$0.05 (-0.42%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+60.7%upside
Target: $18.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.70 – $11.94
TARGET (TP)$19.00
STOP LOSS$10.87
RISK/REWARD1:7.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.59
52W High$20.12
52W Low$9.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.78B | $6.08B | $6.83B | $6.34B | $4.97B |
| Gross Profit | $1.15B | $1.31B | $1.62B | $1.38B | $1.07B |
| Gross Margin | 19.9% | 21.5% | 23.7% | 21.8% | 21.5% |
| Operating Income | $443.00M | $-123,000,000 | $786.00M | $674.00M | $448.00M |
| Net Income | $86.00M | $-238,000,000 | $578.00M | $608.00M | $219.00M |
| Net Margin | 1.5% | -3.9% | 8.5% | 9.6% | 4.4% |
| EPS | $0.58 | $-1.60 | $3.72 | $3.69 | $1.33 |
Company Overview
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and others applications. The Chemical Solutions segment comprises a portfolio of industrial chemicals used as raw materials and catalysts for gold production, clean and disinfect, oil and gas, water treatment, electronics, and automotive applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
47%
Hold / Neutral
6
40%
Sell / Underperform
2
13%
Analyst Consensus🔴 Bearish
7 Bullish8 Neutral/Bearish
Price Targets
$31
Average Target
↑ 162.8% Upside
Now
$19
Low
$31
Average
$44
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 27th 2025 | Mizuho | Upgrade | Outperform | $19 |
| January 28th 2025 | Truist | Initiation | Buy | $27 |
| July 9th 2024 | UBS | Upgrade | Buy | $30← $28 |
| June 7th 2024 | Mizuho | Initiation | Neutral | $25 |
| April 9th 2024 | BMO Capital Markets | Upgrade | Outperform | $34← $19 |
| March 5th 2024 | UBS | Downgrade | Neutral | $21← $37 |
| February 29th 2024 | BMO Capital Markets | Downgrade | Underperform | $19← $45 |
| December 1st 2023 | RBC Capital Mkts | Upgrade | Outperform | $40← $28 |
| June 22nd 2023 | BofA Securities | Downgrade | Neutral | $37← $41 |
| January 24th 2023 | UBS | Upgrade | Buy | $43← $31 |
| January 11th 2023 | BofA Securities | Upgrade | Buy | $40← $37 |
| January 10th 2023 | RBC Capital Mkts | Downgrade | Sector Perform | $33← $35 |
| November 1st 2022 | Credit Suisse | Initiation | Underperform | $24 |
| October 13th 2022 | Goldman | Initiation | Neutral | $30 |
| October 5th 2022 | Argus | Downgrade | Hold | - |
Earnings History & Surprises
CCBeat Rate
67%
Last 18 quarters
Avg Surprise
-32.7%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$0.20
Q4 2025
EPS Surprise History
Q1 24
+6.9%
$0.31vs$0.29
Q2 24
+77.8%
$0.32vs$0.18
Q3 24
-33.3%
$0.38vs$0.57
Q4 24
+25.0%
$0.40vs$0.32
Q1 25
+10.0%
$0.11vs$0.10
Q2 25
-31.6%
$0.13vs$0.19
Q3 25
+26.1%
$0.58vs$0.46
Q4 25
-16.7%
$0.20vs$0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | $0.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.24 | $0.20 | -16.7% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $0.46 | $0.58 | +26.1% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.19 | $0.13 | -31.6% | ✗ MISS |
Q1 2025 | Feb 18, 2025 | $0.10 | $0.11 | +10.0% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.32 | $0.40 | +25.0% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $0.57 | $0.38 | -33.3% | ✗ MISS |
Q2 2024 | Apr 30, 2024 | $0.18 | $0.32 | +77.8% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $0.29 | $0.31 | +6.9% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.77 | $0.64 | -16.9% | ✗ MISS |
Q3 2023 | Jul 27, 2023 | $1.09 | $1.10 | +0.9% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $0.47 | $0.98 | +108.5% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $0.08 | $-0.65 | -908.1% | ✗ MISS |
Q4 2022 | Oct 25, 2022 | $1.04 | $1.24 | +19.2% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $1.42 | $1.89 | +33.1% | ✓ BEAT |
Q2 2022 | May 2, 2022 | $0.92 | $1.46 | +58.7% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $0.87 | $0.81 | -6.9% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $1.02 | $1.27 | +24.5% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.89 | $1.20 | +34.8% | ✓ BEAT |
Latest News
JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $13
➖ NeutralBenzinga•Dec 3, 2025, 04:04 PM
UBS Maintains Buy on Chemours, Lowers Price Target to $18
➖ NeutralBenzinga•Nov 11, 2025, 08:57 PM•Also:
Truist Securities Maintains Buy on Chemours, Lowers Price Target to $18
➖ NeutralBenzinga•Nov 10, 2025, 05:11 PM
RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $17
➖ NeutralBenzinga•Nov 10, 2025, 04:08 PM
Chemours Sees FY2025 Sales $5.700B-$5.800B vs $5.882B Est
📉 NegativeBenzinga•Nov 6, 2025, 10:57 PM
Chemours Sees Q4 Sales $1.271B-$1.345B vs $1.394B Est
📉 NegativeBenzinga•Nov 6, 2025, 09:40 PM
Chemours Q3 Adj. EPS $0.20 Misses $0.25 Estimate, Sales $1.495B Miss $1.498B Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:35 PM
Mizuho Maintains Outperform on Chemours, Lowers Price Target to $18
➖ NeutralBenzinga•Oct 16, 2025, 01:25 PM
UBS Maintains Buy on Chemours, Raises Price Target to $21
📈 PositiveBenzinga•Oct 6, 2025, 04:27 PM
Mizuho Maintains Outperform on Chemours, Raises Price Target to $19
📈 PositiveBenzinga•Sep 23, 2025, 01:09 PM
Truist Securities Maintains Buy on Chemours, Raises Price Target to $21
📈 PositiveBenzinga•Sep 16, 2025, 02:47 PM
Chemours Names Mary Cranston Board Chair And Appoints Alister Cowan Lead Independent Director Following Dawn Farrell Departure
➖ NeutralBenzinga•Sep 3, 2025, 10:48 AM
Chemours Chair Dawn Farrell Resigns Effective Sept. 2 To Lead Canadian Government's New Major Projects Office
➖ NeutralBenzinga•Aug 29, 2025, 08:37 PM
Chemours Strengthens Global Supply Chain With SRF Limited Partnership In India Supporting Semiconductor Automotive And Aerospace Applications
📈 PositiveBenzinga•Aug 19, 2025, 09:36 AM
Chemours surges to five-month high after cooling fluid qualifies with Samsung SSDs
📈 PositiveSeeking Alpha•Aug 13, 2025, 10:44 PM•Also:
Chemours surges to highest since March as EPA pulls plan to rewrite asbestos phaseout rule
📈 PositiveSeeking Alpha•Jul 8, 2025, 04:13 PM
Chemours foresees strong Q2 sales increase on strong refrigerant demand
📈 PositiveSeeking Alpha•Jun 18, 2025, 07:41 PM
Frequently Asked Questions about CC
What is CC's current stock price?
The Chemours Company (CC) is currently trading at $11.82 per share. The stock has moved -0.42% today.
What is the analyst price target for CC?
The average analyst price target for CC is $19.00, based on 1 analyst.
What sector is The Chemours Company in?
The Chemours Company operates in the Basic Materials sector, specifically within the Chemicals - Specialty industry. The company is traded on the NYSE exchange.
What is CC's market cap?
The Chemours Company has a market capitalization of $1.77 billion, making it a small-cap company.
Does CC pay dividends?
No, The Chemours Company does not currently pay a dividend to shareholders.
Similar Stocks
Basic Materials SectorAPD
Air Products and Chemicals, Inc.
$239.96
Mkt Cap: $53.4B
ASH
Ashland Inc.
$59.46
Mkt Cap: $2.7B
AXTA
Axalta Coating Systems Ltd.
$32.06
Mkt Cap: $7.0B
CBT
Cabot Corporation
$66.13
Mkt Cap: $3.5B
ECVT
Ecovyst Inc.
$9.59
Mkt Cap: $1.1B
ESI
Element Solutions Inc
$25.16
Mkt Cap: $6.1B
FF
FutureFuel Corp.
$3.41
Mkt Cap: $0.1B
FUL
H.B. Fuller Company
$59.89
Mkt Cap: $3.2B
IFF
International Flavors & Fragrances Inc.
$65.77
Mkt Cap: $16.8B
KWR
Quaker Chemical Corporation
$144.90
Mkt Cap: $2.5B
Explore stocks similar to CC for comparison